Pinnacle Medicines raised $89 million to advance oral peptide therapeutics engineered to deliver injectable-biologic-like properties. The startup says its lead program, incubated with OrbiMed, is on track to enter the clinic in asthma and chronic obstructive pulmonary disease. The financing underscores continued investor appetite for oral delivery platforms that can overcome long-standing peptide development hurdles, including stability and absorption. Pinnacle’s stated clinical plan targets respiratory disease areas where repeated dosing and long-term adherence are central. By positioning oral peptides as a functional alternative to injectables, the company is pitching a potential route to expand the biologic-like efficacy frontier while improving dosing convenience for patients. Investors will likely watch how Pinnacle translates platform claims into early human exposure, tolerability, and pharmacodynamic signals as the program moves toward first-in-human studies.